Last Updated : May 7, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Idhifa | Enasidenib | Acute myeloid leukemia (AML) | Do not reimburse | Complete | ||
Tramacet | Tramadol hydrochloride /acetaminophen | Acute pain | Do not list | Complete | ||
Trisenox | Arsenic Trioxide | Acute Promyelocytic Leukemia | Reimburse | Complete | ||
Verzenio | abemaciclib | Adjuvant treatment of HR-positive, HER2-negative early breast cancer | Active | |||
Verzenio | abemaciclib | Adjuvant treatment of HR-positive, HER2-negative early breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Afinitor | Everolimus | Advanced Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Ibrance Resubmission | Palbociclib | Advanced breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Libtayo | Cemiplimab | Advanced Cutaneous Squamous Cell Carcinoma (CSCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda and Lenvima | pembrolizumab and lenvatinib | Advanced endometrial cancer | Withdrawn | |||
Keytruda and Lenvima | pembrolizumab and lenvatinib | Advanced endometrial cancer | Reimburse with clinical criteria and/or conditions | Complete |